azt-008 Search Results


anti human zip8  (Alomone Labs)
93
Alomone Labs anti human zip8
A Schematic workflow of the high-throughput screening to identify ZIP14 inhibitors. B Chemical structure of 1-phenyl-8-(2-phenylethyl)-1,3,8-triazaspiro[4.5]decan-4-one (PPTD).
Anti Human Zip8, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/azt-008/Anti-ZIP8+(SLC39A8)+(extracellular)+Antibody/bio_rxiv__2025__10__23__682519-134-11-13
Average 93 stars, based on 1 article reviews
anti human zip8 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


A Schematic workflow of the high-throughput screening to identify ZIP14 inhibitors. B Chemical structure of 1-phenyl-8-(2-phenylethyl)-1,3,8-triazaspiro[4.5]decan-4-one (PPTD).

Journal: bioRxiv

Article Title: Discovery of a Selective Inhibitor of ZIP14 with Therapeutic Potential for Cancer-associated Cachexia

doi: 10.1101/2025.10.23.682519

Figure Lengend Snippet: A Schematic workflow of the high-throughput screening to identify ZIP14 inhibitors. B Chemical structure of 1-phenyl-8-(2-phenylethyl)-1,3,8-triazaspiro[4.5]decan-4-one (PPTD).

Article Snippet: The following primary antibodies were used: anti-human ZIP14 (generated previously ), anti-human ZIP8 (Alomone Labs, #AZT-008), and anti-β-actin (Cell Signaling Technology, #3700S).

Techniques: Sample Throughput, Screening

Xenopus oocytes injected either with ( A, B ) human ZIP14 or ( E, F ) human ZIP8 cRNA were incubated with either ( A, E ) ⁶⁵Zn or ( B, F ) ⁵⁵Fe in the presence of ( A, E ) 50 µM or ( B, F ) 10 µM PPTD for 30 min at 22 °C. Radioactivity was measured as described under Methods . Data are normalized against DMSO-treated transporter-expressing controls, and presented as mean ± standard deviation (S.D.) (n=3 independent experiments). Similarly, (C, D) TREx-hZIP14 or (G, H) TREx-hZIP8 cells were treated with Tet (1 μg/mL) for 24 h, followed by incubation either with ( C, G ) ⁵⁴MnCl₂ or (D, H) ¹⁰⁹CdCl₂ in the presence of PPTD at the indicated concentrations for 1 h. Radioactivity was measured as described under Methods . The data (mean + SD) represent results from three independent experiments. Statistical significance was determined using Student’s t -test (A, B, E, F) or one-way ANOVA followed by Dunnett’s post hoc test (C, D, G, H). (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ***** p < 0.0005).

Journal: bioRxiv

Article Title: Discovery of a Selective Inhibitor of ZIP14 with Therapeutic Potential for Cancer-associated Cachexia

doi: 10.1101/2025.10.23.682519

Figure Lengend Snippet: Xenopus oocytes injected either with ( A, B ) human ZIP14 or ( E, F ) human ZIP8 cRNA were incubated with either ( A, E ) ⁶⁵Zn or ( B, F ) ⁵⁵Fe in the presence of ( A, E ) 50 µM or ( B, F ) 10 µM PPTD for 30 min at 22 °C. Radioactivity was measured as described under Methods . Data are normalized against DMSO-treated transporter-expressing controls, and presented as mean ± standard deviation (S.D.) (n=3 independent experiments). Similarly, (C, D) TREx-hZIP14 or (G, H) TREx-hZIP8 cells were treated with Tet (1 μg/mL) for 24 h, followed by incubation either with ( C, G ) ⁵⁴MnCl₂ or (D, H) ¹⁰⁹CdCl₂ in the presence of PPTD at the indicated concentrations for 1 h. Radioactivity was measured as described under Methods . The data (mean + SD) represent results from three independent experiments. Statistical significance was determined using Student’s t -test (A, B, E, F) or one-way ANOVA followed by Dunnett’s post hoc test (C, D, G, H). (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ***** p < 0.0005).

Article Snippet: The following primary antibodies were used: anti-human ZIP14 (generated previously ), anti-human ZIP8 (Alomone Labs, #AZT-008), and anti-β-actin (Cell Signaling Technology, #3700S).

Techniques: Injection, Incubation, Radioactivity, Expressing, Standard Deviation

TREx-hZIP14 cells were treated with Tet (1 μg/mL) in combination with ( A ) ZnSO 4 (100 μM), ( B ) FeSO 4 (20 μM), ( C ) MnCl₂ (100 μM), or ( D ) CdCl₂ (20 μM), with or without PPTD at the indicated concentrations. Similarly, TREx-hZIP8 cells were treated under the same conditions ( E–H ). Phase-contrast images showing cell morphology ( A, B, E, F ). Cell viability ( C, D, G, H ) was quantified as described under Methods , and representative data (mean + SD) from three independent experiments are presented. Statistical significance was determined using one-way ANOVA followed by Dunnett’s post hoc test ( C, D, G, H ). (* p < 0.05, *** p < 0.005, **** p < 0.001, ***** p < 0.0005). Scale bar: 20 μm.

Journal: bioRxiv

Article Title: Discovery of a Selective Inhibitor of ZIP14 with Therapeutic Potential for Cancer-associated Cachexia

doi: 10.1101/2025.10.23.682519

Figure Lengend Snippet: TREx-hZIP14 cells were treated with Tet (1 μg/mL) in combination with ( A ) ZnSO 4 (100 μM), ( B ) FeSO 4 (20 μM), ( C ) MnCl₂ (100 μM), or ( D ) CdCl₂ (20 μM), with or without PPTD at the indicated concentrations. Similarly, TREx-hZIP8 cells were treated under the same conditions ( E–H ). Phase-contrast images showing cell morphology ( A, B, E, F ). Cell viability ( C, D, G, H ) was quantified as described under Methods , and representative data (mean + SD) from three independent experiments are presented. Statistical significance was determined using one-way ANOVA followed by Dunnett’s post hoc test ( C, D, G, H ). (* p < 0.05, *** p < 0.005, **** p < 0.001, ***** p < 0.0005). Scale bar: 20 μm.

Article Snippet: The following primary antibodies were used: anti-human ZIP14 (generated previously ), anti-human ZIP8 (Alomone Labs, #AZT-008), and anti-β-actin (Cell Signaling Technology, #3700S).

Techniques: Phase Contrast, Morphology